Stefan Dübel

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1826398/publications.pdf

Version: 2024-02-01

185 papers 7,502 citations

³⁸⁷⁴² 50 h-index

77 g-index

307 all docs

307 docs citations

307 times ranked 7053 citing authors

#	Article	IF	CITATIONS
1	Beyond natural antibodies: the power of in vitro display technologies. Nature Biotechnology, 2011, 29, 245-254.	17.5	482
2	A surface expression vector for antibody screening. Gene, 1991, 104, 147-153.	2.2	312
3	A helper phage to improve single-chain antibody presentation in phage display. Nature Biotechnology, 2001, 19, 75-78.	17.5	265
4	ProteomeBinders: planning a European resource of affinity reagents for analysis of the human proteome. Nature Methods, 2007, 4, 13-17.	19.0	231
5	The Translocon Protein Sec61 Mediates Antigen Transport from Endosomes in the Cytosol for Cross-Presentation to CD8+ T Cells. Immunity, 2015, 42, 850-863.	14.3	136
6	Mating antibody phage display with proteomics. Trends in Biotechnology, 2004, 22, 8-14.	9.3	134
7	A human scFv antibody generation pipeline for proteome research. Journal of Biotechnology, 2011, 152, 159-170.	3.8	127
8	Targeting Recombinant Antibodies to the Surface of Escherichia coli: Fusion to a Peptidoglycan Associated Lipoprotein. Bio/technology, 1991, 9, 1369-1372.	1.5	115
9	Generation and analysis of the improved human HAL9/10 antibody phage display libraries. BMC Biotechnology, 2015, 15, 10.	3.3	115
10	Single chain Fab (scFab) fragment. BMC Biotechnology, 2007, 7, 14.	3.3	113
11	A comparative study of different vector designs for the mammalian expression of recombinant IgG antibodies. Journal of Immunological Methods, 2007, 318, 113-124.	1.4	110
12	High-Affinity, Human Antibody-Like Antibody Fragment (Single-Chain Variable Fragment) Neutralizing the Lethal Factor (LF) of Bacillus anthracis by Inhibiting Protective Antigen-LF Complex Formation. Antimicrobial Agents and Chemotherapy, 2007, 51, 2758-2764.	3.2	105
13	Generating recombinant antibodies to the complete human proteome. Trends in Biotechnology, 2010, 28, 333-339.	9.3	98
14	Molecular Cloning of Tissue-Specific Transcripts of a Transketolase-Related Gene: Implications for the Evolution of New Vertebrate Genes. Genomics, 1996, 32, 309-316.	2.9	96
15	Targeting antibodies to the cytoplasm. MAbs, 2011, 3, 3-16.	5.2	93
16	On the influence of vector design on antibody phage display. Journal of Biotechnology, 2007, 127, 626-637.	3.8	90
17	Specific <i>in vivo</i> knockdown of protein function by intrabodies. MAbs, 2015, 7, 1010-1035.	5.2	89
18	Recombinant single-chain Fv fragments carrying C-terminal cysteine residues: Production of bivalent and biotinylated miniantibodies. Molecular Immunology, 1994, 31, 1047-1058.	2.2	84

#	Article	IF	CITATIONS
19	The influence of antibody fragment format on phage display based affinity maturation of IgG. MAbs, 2014, 6, 204-218.	5.2	84
20	Phage Display Derived Therapeutic Antibodies. Current Pharmaceutical Biotechnology, 2008, 9, 439-446.	1.6	84
21	Affinity enhancement of a recombinant antibody: formation of complexes with multiple valency by a single-chain Fv fragment–core streptavidin fusion. Protein Engineering, Design and Selection, 1996, 9, 203-211.	2.1	82
22	Isolation of a human-like antibody fragment (scFv) that neutralizes ricin biological activity. BMC Biotechnology, 2009, 9, 60.	3.3	82
23	Designing Human Antibodies by Phage Display. Transfusion Medicine and Hemotherapy, 2017, 44, 312-318.	1.6	78
24	NF-l $^{\circ}$ B inhibitor targeted to activated endothelium demonstrates a critical role of endothelial NF-l $^{\circ}$ B in immune-mediated diseases. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 16556-16561.	7.1	77
25	Production systems for recombinant antibodies. Frontiers in Bioscience - Landmark, 2008, Volume, 4576.	3.0	75
26	A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations. Cell Reports, 2021, 36, 109433.	6.4	75
27	When monoclonal antibodies are not monospecific: Hybridomas frequently express additional functional variable regions. MAbs, 2018, 10, 539-546.	5.2	74
28	Identification of Epitope Regions Recognized by Tumor Inhibitory and Stimulatory Anti-ErbB-2 Monoclonal Antibodies: Implications for Vaccine Design. Journal of Immunology, 2001, 166, 5271-5278.	0.8	73
29	Development of human antibody fragments using antibody phage display for the detection and diagnosis of Venezuelan equine encephalitis virus (VEEV). BMC Biotechnology, 2008, 8, 66.	3.3	73
30	SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface. Nature Communications, 2021, 12, 1577.	12.8	73
31	Rise and Fall of an Anti-MUC1 Specific Antibody. PLoS ONE, 2011, 6, e15921.	2.5	73
32	Effects of unpaired cysteines on yield, solubility and activity of different recombinant antibody constructs expressed in E. coli. Journal of Immunological Methods, 2000, 242, 101-114.	1.4	72
33	Human antibody RNase fusion protein targeting CD30+ lymphomas. Blood, 2008, 111, 3830-3837.	1.4	72
34	Perspectives for systematic in vitro antibody generation. Gene, 2005, 364, 19-29.	2.2	71
35	Differentiation pathways of ectodermal epithelial cells in hydra. Differentiation, 1987, 35, 181-189.	1.9	70
36	Functional Characterization of Recombinant Chloroplast Signal Recognition Particle. Journal of Biological Chemistry, 2001, 276, 27778-27786.	3.4	70

#	Article	IF	CITATIONS
37	Delivery of antibodies to the cytosol. MAbs, 2014, 6, 943-956.	5.2	67
38	Human serum from SARS-CoV-2-vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant. BMC Medicine, 2022, 20, 102.	5. 5	67
39	Identification of a Putative Crf Splice Variant and Generation of Recombinant Antibodies for the Specific Detection of Aspergillus fumigatus. PLoS ONE, 2009, 4, e6625.	2.5	63
40	Cloning and cytotoxicity of a human pancreatic RNase immunofusion. Immunotechnology: an International Journal of Immunological Engineering, 1997, 3, 127-136.	2.4	60
41	Recombinant therapeutic antibodies. Applied Microbiology and Biotechnology, 2007, 74, 723-729.	3.6	60
42	Baculovirus expression cassette vectors for rapid production of complete human IgG from phage display selected antibody fragments. Journal of Immunological Methods, 2001, 247, 119-130.	1.4	59
43	Recombinant Antibodies and In Vitro Selection Technologies. Methods in Molecular Biology, 2012, 901, 11-32.	0.9	59
44	Identification of Immunogenic Antigens from <i>Aspergillus fumigatus</i> by Direct Multiparameter Characterization of Specific Conventional and Regulatory CD4+ T Cells. Journal of Immunology, 2014, 193, 3332-3343.	0.8	58
45	Animal-free alternatives and the antibody iceberg. Nature Biotechnology, 2020, 38, 1234-1239.	17.5	58
46	Isolation of IgG antibody Fv-DNA from various mouse and rat hybridoma cell lines using the polymerase chain reaction with a simple set of primers. Journal of Immunological Methods, 1994, 175, 89-95.	1.4	56
47	Measuring Biomolecular Binding Events with a Compact Disc Player Device. Angewandte Chemie - International Edition, 2006, 45, 270-273.	13.8	56
48	Targeted therapeutic RNases (ImmunoRNases). Expert Opinion on Biological Therapy, 2009, 9, 79-95.	3.1	56
49	Parameters affecting the display of antibodies on phage. Journal of Immunological Methods, 2005, 301, 173-185.	1.4	54
50	Antibodies inside of a cell can change its outside: Can intrabodies provide a new therapeutic paradigm?. Computational and Structural Biotechnology Journal, 2016, 14, 304-308.	4.1	54
51	SRP and Sec pathway leader peptides for antibody phage display and antibody fragment production in E. coli. New Biotechnology, 2008, 25, 49-54.	4.4	53
52	Towards proteome scale antibody selections using phage display. New Biotechnology, 2010, 27, 118-128.	4.4	53
53	cTAGE: A Cutaneous T Cell Lymphoma Associated Antigen Family with Tumor-Specific Splicing. Journal of Investigative Dermatology, 2003, 121, 198-206.	0.7	52
54	Human antibodies neutralizing diphtheria toxin in vitro and in vivo. Scientific Reports, 2020, 10, 571.	3.3	52

#	Article	IF	Citations
55	Minimum information about a protein affinity reagent (MIAPAR). Nature Biotechnology, 2010, 28, 650-653.	17.5	50
56	The INNs and outs of antibody nonproprietary names. MAbs, 2016, 8, 1-9.	5.2	48
57	Analysis of IgG heavy chain to light chain ratio with mutant Encephalomyocarditis virus internal ribosome entry site. Protein Engineering, Design and Selection, 2007, 20, 491-496.	2.1	47
58	Affinity Maturation by Phage Display. Methods in Molecular Biology, 2009, 525, 309-322.	0.9	46
59	Enrichment of open reading frames presented on bacteriophage M13 using Hyperphage. BioTechniques, 2006, 41, 335-342.	1.8	45
60	A multi-Fc-species system for recombinant antibody production. BMC Biotechnology, 2009, 9, 14.	3.3	45
61	Efficient production of soluble recombinant single chain Fv fragments by a Pseudomonas putida strain KT2440 cell factory. Microbial Cell Factories, 2011, 10, 11.	4.0	45
62	Single amino acid fingerprinting of the human antibody repertoire with high density peptide arrays. Journal of Immunological Methods, 2017, 443, 45-54.	1.4	45
63	Production of recombinant antibody fragments in Bacillus megaterium. Microbial Cell Factories, 2007, 6, 2.	4.0	44
64	Improved microtitre plate production of single chain Fv fragments in Escherichia coli. New Biotechnology, 2009, 25, 424-428.	4.4	43
65	Isolation and Characterisation of a Human-Like Antibody Fragment (scFv) That Inactivates VEEV In Vitro and In Vivo. PLoS ONE, 2012, 7, e37242.	2.5	41
66	Cellâ€free eukaryotic systems for the production, engineering, and modification of scFv antibody fragments. Engineering in Life Sciences, 2014, 14, 387-398.	3.6	41
67	Developing Recombinant Antibodies by Phage Display Against Infectious Diseases and Toxins for Diagnostics and Therapy. Frontiers in Cellular and Infection Microbiology, 2021, 11, 697876.	3.9	40
68	Expression of a bispecific dsFvâ€"dsFvâ€2 antibody fragment in Escherichia coli. Protein Engineering, Design and Selection, 2000, 13, 725-734.	2.1	38
69	Phage Display Vectors for the In Vitro Generation of Human Antibody Fragments. , 2005, 295, 71-96.		38
70	Cytosolic Delivery of Macromolecules in Live Human Cells Using the Combined Endosomal Escape Activities of a Small Molecule and Cell Penetrating Peptides. ACS Chemical Biology, 2019, 14, 2641-2651.	3.4	38
71	A Community Standard Format for the Representation of Protein Affinity Reagents. Molecular and Cellular Proteomics, 2010, 9, 1-10.	3.8	35
72	A vector for the removal of deletion mutants from antibody libraries. Gene, 1992, 114, 235-237.	2,2	34

#	Article	IF	Citations
73	Epitope structures recognised by antibodies against the major coat protein (g8p) of filamentous bacteriophage fd (Inoviridae). Journal of Molecular Biology, 1999, 288, 21-28.	4.2	34
74	Cell-Type Targeted NF-kappaB Inhibition for the Treatment of Inflammatory Diseases. Cells, 2020, 9, 1627.	4.1	34
75	Bacterial expression and refolding of single-chain Fv fragments with C-terminal cysteines. Cell Biophysics, 1995, 26, 187-204.	0.4	32
76	Separation of E. coli expressing functional cell-wall bound antibody fragments by FACS. Immunotechnology: an International Journal of Immunological Engineering, 1996, 2, 97-102.	2.4	32
77	Characterization of the Epitope Recognized by a Monoclonal Antibody Directed against the Largest Subunit ofDrosophilaRNA Polymerase II. Biological Chemistry Hoppe-Seyler, 1995, 376, 473-482.	1.4	31
78	Identification of immunogenic proteins and generation of antibodies against Salmonella Typhimurium using phage display. BMC Biotechnology, 2012, 12, 29.	3.3	31
79	Modeling Neurodegenerative Spinocerebellar Ataxia Type 13 in Zebrafish Using a Purkinje Neuron Specific Tunable Coexpression System. Journal of Neuroscience, 2019, 39, 3948-3969.	3.6	31
80	Selection of Recombinant Antibodies From Antibody Gene Libraries. Methods in Molecular Biology, 2007, 408, 243-255.	0.9	30
81	Baculovirus-free insect cell expression system for high yield antibody and antigen production. Scientific Reports, 2020, 10, 21393.	3.3	30
82	Cell differentiation in the head of Hydra. Differentiation, 1989, 41, 99-109.	1.9	29
83	V-gene amplification revisited – An optimised procedure for amplification of rearranged human antibody genes of different isotypes. New Biotechnology, 2010, 27, 108-117.	4.4	29
84	Single-chain antibody streptavidin fusions: Tetrameric bifunctional scFv-complexes with biotin binding activity and enhanced affinity to antigen. Human Antibodies, 1995, 6, 93-101.	1.5	28
85	Isolation of scFv fragments specific to OmpD of Salmonella Typhimurium. Veterinary Microbiology, 2011, 147, 162-169.	1.9	28
86	New anti-CD30 human pancreatic ribonuclease-based immunotoxin reveals strong and specific cytotoxicityin vivo. Leukemia and Lymphoma, 2007, 48, 1179-1186.	1.3	27
87	Human-like antibodies neutralizing Western equine encephalitis virus. MAbs, 2014, 6, 717-726.	5.2	27
88	Animal-derived-antibody generation faces strict reform in accordance with European Union policy on animal use. Nature Methods, 2020, 17, 755-756.	19.0	27
89	Production of single chain Fab (scFab) fragments in Bacillus megaterium. Microbial Cell Factories, 2007, 6, 38.	4.0	26
90	Suppression of p75 Neurotrophin Receptor Surface Expression with Intrabodies Influences Bcl-xL mRNA Expression and Neurite Outgrowth in PC12 Cells. PLoS ONE, 2012, 7, e30684.	2.5	25

#	Article	IF	CITATIONS
91	Cloning Single-Chain Antibody Fragments (scFv) from Hybridoma Cells. , 2004, 94, 447-458.		23
92	Screening of Molecular Repertoires by Microbial Surface Display. Combinatorial Chemistry and High Throughput Screening, 2005, 8, 127-133.	1.1	23
93	Production of single chain fragment variable (scFv) antibodies in Escherichia coli using the LEXâ,,¢ bioreactor. Journal of Biotechnology, 2013, 163, 105-111.	3.8	23
94	Functional knockdown of VCAM-1 at the posttranslational level with ER retained antibodies. Journal of Immunological Methods, 2009, 341, 30-40.	1.4	22
95	Phage display-based identification and potential diagnostic application of novel antigens from Mycoplasma mycoides subsp. mycoides small colony type. Veterinary Microbiology, 2010, 142, 285-292.	1.9	22
96	Functional knock down of VCAM1 in mice mediated by endoplasmatic reticulum retained intrabodies. MAbs, 2014, 6, 1394-1401.	5.2	22
97	Surface display of antibodies. Biotechnology Advances, 1994, 12, 539-555.	11.7	21
98	Antibody production in <i>Bacillus megaterium</i> : Strategies and physiological implications of scaling from microtiter plates to industrial bioreactors. Biotechnology Journal, 2011, 6, 1516-1531.	3.5	20
99	Construction of Human Naive Antibody Gene Libraries. Methods in Molecular Biology, 2012, 907, 85-107.	0.9	20
100	Novel human recombinant antibodies against Mycobacterium tuberculosis antigen 85B. BMC Biotechnology, 2014, 14, 68.	3.3	20
101	Human antibody libraries in Escherichia coli. Journal of Biotechnology, 1995, 41, 187-195.	3.8	19
102	Mining gut microbiome oligopeptides by functional metaproteome display. Scientific Reports, 2016, 6, 34337.	3.3	19
103	Inhibition of HER3 activation and tumor growth with a human antibody binding to a conserved epitope formed by domain III and IV. MAbs, 2017, 9, 831-843.	5.2	19
104	Radiometal-labeled anti-VCAM-1 nanobodies as molecular tracers for atherosclerosis – impact of radiochemistry on pharmacokinetics. Biological Chemistry, 2019, 400, 323-332.	2.5	19
105	Development of Neutralizing and Non-neutralizing Antibodies Targeting Known and Novel Epitopes of TcdB of Clostridioides difficile. Frontiers in Microbiology, 2018, 9, 2908.	3.5	18
106	Reproducibility: bypass animals for antibody production. Nature, 2020, 581, 262-262.	27.8	17
107	Identification of a new epitope for HIVâ€neutralizing antibodies in the gp41 membrane proximal external region by an Envâ€tailored phage display library. European Journal of Immunology, 2013, 43, 499-509.	2.9	16
108	Quantification of polyreactive immunoglobulin G facilitates the diagnosis of autoimmune hepatitis. Hepatology, 2022, 75, 13-27.	7.3	16

#	Article	IF	CITATIONS
109	Fine mapping of the antigen-antibody interaction of scFv215, a recombinant antibody inhibiting RNA polymerase II fromDrosophila melanogaster., 1999, 12, 103-111.		15
110	Oligomeric forms of single chain immunoglobulin (sclgG). MAbs, 2010, 2, 73-76.	5.2	15
111	Low-cost, in-liquid measuring system using a novel compact oscillation circuit and quartz-crystal microbalancesÂ(QCMs) as a versatile biosensor platform. Journal of Sensors and Sensor Systems, 2017, 6, 341-350.	0.9	15
112	Rapid Titration of Multiple Samples of Filamentous Bacteriophage (M13) on Nitrocellulose Filters. BioTechniques, 2000, 29, 1196-1202.	1.8	14
113	The Rapeutic Antibodies and Antibody Fusion Proteins. Biotechnology and Genetic Engineering Reviews, 2003, 20, 137-164.	6.2	14
114	Mutations in the N-Terminus of the Major Coat Protein (pVIII, gp8) of Filamentous Bacteriophage Affect Infectivity. Journal of Molecular Microbiology and Biotechnology, 2003, 6, 57-66.	1.0	14
115	Antibody-Targeted RNase Fusion Proteins (ImmunoRNases) for Cancer Therapy. Current Pharmaceutical Biotechnology, 2008, 9, 231-234.	1.6	14
116	Influence of the hydromechanical stress and temperature on growth and antibody fragment production with Bacillus megaterium. Applied Microbiology and Biotechnology, 2011, 91, 81-90.	3.6	14
117	A strategy to identify linker-based modules for the allosteric regulation of antibody-antigen binding affinities of different scFvs. MAbs, 2017, 9, 404-418.	5. 2	14
118	Directed evolution of super-secreted variants from phage-displayed human Interleukin-2. Scientific Reports, 2019, 9, 800.	3.3	14
119	Primary Structure and Functional scFv Antibody Expression of an Antibody Against the Human Protooncogen c-myc. Hybridoma, 1997, 16, 227-233.	0.6	13
120	Selection of Recombinant Antibodies from Antibody Gene Libraries. Methods in Molecular Biology, 2014, 1101, 305-320.	0.9	13
121	Embryonic zebrafish primary cell culture for transfection and live cellular and subcellular imaging. Developmental Biology, 2017, 430, 18-31.	2.0	13
122	Structural differences of amyloid- \hat{l}^2 fibrils revealed by antibodies from phage display. BMC Biotechnology, 2015, 15, 57.	3.3	12
123	Sequence defined antibodies improve the detection of cadherin 2 (N-cadherin) during zebrafish development. New Biotechnology, 2018, 45, 98-112.	4.4	12
124	Recent Advances with ER Targeted Intrabodies. Advances in Experimental Medicine and Biology, 2016, 917, 77-93.	1.6	11
125	Pyruvate dehydrogenase complex—enzyme 2, a new target for Listeria spp. detection identified using combined phage display technologies. Scientific Reports, 2020, 10, 15267.	3.3	11
126	Animal-versus <i>in vitro</i> -derived antibodies: avoiding the extremes. MAbs, 2021, 13, 1950265.	5 . 2	11

#	Article	IF	Citations
127	Hyperphage: Improving Antibody Presentation in Phage Display. , 2003, 205, 295-302.		10
128	Human antibodies targeting CD30+ lymphomas. Human Antibodies, 2012, 21, 13-28.	1.5	10
129	Single Chain Antibodies as Tools to Study transforming growth factor- \hat{l}^2 -Regulated SMAD Proteins in Proximity Ligation-Based Pharmacological Screens. Molecular and Cellular Proteomics, 2016, 15, 1848-1856.	3.8	10
130	Utilisation of antibody microarrays for the selection of specific and informative antibodies from recombinant library binders of unknown quality. New Biotechnology, 2016, 33, 574-581.	4.4	10
131	Human Anti-Lipopolysaccharid (LPS) antibodies against Legionella with high species specificity. Human Antibodies, 2019, 26, 29-38.	1.5	10
132	Analysis of Protein Interactions with Immobilized Peptide Arrays Synthesized on Membrane Supports. Cold Spring Harbor Protocols, 2006, 2006, pdb.prot4566-pdb.prot4566.	0.3	10
133	Protein stabilization through phage display. FEBS Letters, 2000, 476, 296-300.	2.8	9
134	Evaluation of human pancreatic RNase as effector molecule in a therapeutic antibody platform. MAbs, 2014, 6, 367-380.	5. 2	9
135	Terminal differentiation of head- and foot-specific epithelial cells occurs at the same location in hydra tissue without polarity. Developmental Biology, 1990, 138, 243-245.	2.0	8
136	Design, construction, and in vitro analysis of A33scFv::CDy, a recombinant fusion protein for antibody-directed enzyme prodrug therapy in colon cancer. International Journal of Oncology, 2007, 31, 951.	3.3	8
137	Recombinant antibody fragments allow repeated measurements of C-reactive protein with a quartz crystal microbalance immunosensor. MAbs, 2013, 5, 140-149.	5.2	8
138	ORFeome Phage Display. Methods in Molecular Biology, 2018, 1701, 477-495.	0.9	8
139	Primary structure of the antigen-binding domains of a human oligodendrocyte-reactive IgM monoclonal antibody derived from a patient with multiple sclerosis. Journal of Neuroimmunology, 1999, 99, 122-130.	2.3	7
140	Evaluating the Delivery of Proteins to the Cytosol of Mammalian Cells. Methods in Molecular Biology, 2017, 1513, 201-208.	0.9	7
141	Structural insights into antigen recognition of an anti- \hat{l}^2 - $(1,6)$ - \hat{l}^2 - $(1,3)$ -D-glucan antibody. Scientific Reports, 2018, 8, 13652.	3.3	7
142	Shelf-Life Extension of Fc-Fused Single Chain Fragment Variable Antibodies by Lyophilization. Frontiers in Cellular and Infection Microbiology, 2021, 11, 717689.	3.9	7
143	Affinity-matured variants derived from nimotuzumab keep the original fine specificity and exhibit superior biological activity. Scientific Reports, 2020, 10, 1194.	3.3	6
144	The antibody web. Trends in Immunology, 2000, 21, 355-357.	7.5	5

#	Article	IF	Citations
145	Cloning of Variable Domains from Mouse Hybridoma by PCR. , 2010, , 3-14.		5
146	Human Antibody Gene Libraries. , 2010, , 65-84.		5
147	Generation of Recombinant Antibodies against the beta-(1,6)-Branched beta-(1,3)-D-Glucan Schizophyllan from Immunized Mice via Phage Display. Biotechnology Research International, 2017, 2017, 1-8.	1.4	5
148	The "Sneaking-Ligand―Approach: Cell-Type Specific Inhibition of the Classical NF-κB Pathway. Methods in Molecular Biology, 2015, 1280, 559-578.	0.9	5
149	Construction of scFv from Hybridoma by Two-Step Cloning. , 2001, , 41-55.		5
150	Primary Structure and Functional Expression of Heavy- and Light-Chain Variable Region Genes of a Monoclonal Antibody Specific for Human Fibrin. Hybridoma, 1997, 16, 235-241.	0.6	4
151	Cloning and Expression of Single-Chain Fragments (SCFV) from Mouse and Rat Hybridomas. , 1998, 13, 581-592.		4
152	ORFeome Phage Display Reveals a Major Immunogenic Epitope on the S2 Subdomain of SARS-CoV-2 Spike Protein. Viruses, 2022, 14, 1326.	3.3	4
153	Rekombinante Antikörper: Werkzeuge gegen Krebs, Infektionen und Autoimmunerkrankungen?. Biologie in Unserer Zeit, 2004, 34, 372-379.	0.2	3
154	The sneaking ligand approach for cell type-specific modulation of intracellular signalling pathways. Clinical Immunology, 2018, 186, 14-20.	3.2	3
155	Antibody fusion proteins with human ribonucleases 1 to 8. Human Antibodies, 2018, 26, 177-192.	1.5	3
156	Generation of Antibody Gene Libraries from Seropositive Human Donors., 2001,, 109-123.		3
157	Phage Display-Derived Monoclonal Antibodies Against Internalins A and B Allow Specific Detection of Listeria monocytogenes. Frontiers in Public Health, 2022, 10, 712657.	2.7	3
158	Intellectual Property Issues., 0,, 301-322.		2
159	Improving Phage Display Throughput by Using Hyperphage, Miniaturized Titration and pVIII (g8p) ELISA. , 2010, , 197-206.		2
160	Culture and Transfection of Zebrafish Primary Cells. Journal of Visualized Experiments, 2018, , .	0.3	2
161	Plant Defense Proteins as Potential Markers for Early Detection of Forest Damage and Diseases. Frontiers in Forests and Global Change, 2021, 4, .	2.3	2
162	Production of Recombinant Human IgG Antibodies in the Baculovirus Expression System. , 2010, , 453-470.		2

#	Article	IF	CITATIONS
163	Recombinant Antibodies. , 2001, , 3-16.		2
164	<i>In vitro</i> evolution of <i>myc-</i> tag antibodies: in-depth specificity and affinity analysis of Myc1-9E10 and Hyper-Myc. Biological Chemistry, 2022, 403, 479-494.	2.5	2
165	Therapeutic Antibodies - From Past to Future. , 0, , 2-16.		1
166	Trendbericht Biochemie 2017: Menschliche Antikörper für Medikamente. Nachrichten Aus Der Chemie, 2018, 66, 284-290.	0.0	1
167	Parallelized Microscale Expression of Soluble scFv. Methods in Molecular Biology, 2019, 2025, 203-211.	0.9	1
168	Rekombinante Antikörper., 2019, , .		1
169	Affinity Measurements of Antibody Fragments on Phage by Quartz Crystal Microbalance (QCM). , 2001, , 397-406.		1
170	Investigation of Conditions for Capture of Live Legionella pneumophila with Polyclonal and Recombinant Antibodies. Biosensors, 2022, 12, 380.	4.7	1
171	Recent Developments in Antibody Engineering. , 1998, 13, 555-580.		0
172	A single chain antibody obtained by cell panning of antibody phage inhibits homoaggregation of human leukemia cells. Human Antibodies, 2005, 13, 111-118.	1.5	0
173	Emerging Technologies for Antibody Selection. , 0, , 431-443.		0
174	Natalizumab (Tysabri)., 0,, 941-950.		0
175	Abciximab, Arcitumomab, Basiliximab, Capromab, Cotara, Daclizumab, Edrecolomab, Ibritumomab, Igovomab, Nofetumomab, Satumomab, Sulesomab, Tositumomab, and Votumumab., 0,, 1131-1147.		0
176	Pharmaceutical Formulation and Clinical Application. , 0, , 239-265.		0
177	Development of Human and Macaque Antibodies Using Antibody Phage Display for the Detection of Equine Encephalitis Viruses. , $2011, , .$		0
178	Patent Issues Relating to Therapeutic Antibodies. , 2014, , 705-734.		0
179	Monoclonal Antibody Nomenclature for Clinical Studies (USA)1. , 2014, , 1283-1288.		0
180	Recent Advances with ER Targeted Intrabodies. , 2015, , 77-93.		0

#	Article	IF	CITATIONS
181	Viele monoklonale Antikörper sind nicht monospezifisch. BioSpektrum, 2018, 24, 395-399.	0.0	0
182	Production of Recombinant Human IgG Antibodies in the Baculovirus Expression System. , 2001, , 334-356.		0
183	Functional Minipreps of scFv-Antibody Fragments. , 2001, , 257-265.		0
184	Using the power of in vitro selection by phage display to identify recombinant antibodies with optimised properties to various life threatening viruses. Journal of Antivirals $\&$ Antiretrovirals, 2011, 02, .	0.1	0
185	Chemiegeschichte: Vom Gen zum Produkt. Nachrichten Aus Der Chemie, 2022, 70, 24-26.	0.0	0